Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 709 participants.
Also called NCT04849000
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 709 participants
- Registry
-
NCT04849000
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04849000. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-23 (actual); primary completion 2022-06-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
- Condition
- Primary Hypercholesterolemia
- Condition
- Mixed Hyperlipemia
- Intervention (Drug)
- SHR-1209
- Intervention (Drug)
- SHR-1209 Placebo
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct04849000- Content hash
3cbd5a0091a5801a303a43536e17a58ea1cadc4e75a9557a38213d2162f55d68